#HURA

2 months ago

#HURA Focus on the Delta Opioid Receptor buff.ly/WGCoOS3

#leukemia #bloodcancer #oncology

0 0 0 0

TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone Milestone Triggers Release of Shares to Kintara Contingent Value Right Holders. TAMPA, Fla., Dec. 15, 2025/ PRNewswire/-- TuHURA Biosciences, Inc., a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that Kintara's REM-001 clinical trial of ten metastatic cutaneous breast cancer...

3 months ago

#HURA TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone

www.stocktitan.net/news/HURA/tu-hura-biosci...

0 0 0 0

TuHURA Biosciences Provides Corporate Update Following Recent Financing TuHURA Biosciences (NASDAQ:HURA) provided a corporate update on December 11, 2025 outlining program milestones, recent financing and scientific data.Key points: the lead Phase 3 IFx-2.0 trial in combination with Keytruda runs under an FDA SPA with enrollment targeted for completion in Q4 2026; a merger added a Phase 2‑ready VISTA antibody (TBS-2025); preclinical and ASH presentations highlighted the Delta Opioid Receptor target and ADC program; and a recent equity financing raised $15.6 million to fund multiple near-term milestones. Management will host a conference call on Dec 11, 2025.

3 months ago

#HURA TuHURA Biosciences Provides Corporate Update Following Recent Financing

www.stocktitan.net/news/HURA/tu-hura-biosci...

0 0 0 0

TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering Sabio (TSXV: SBIO / OTCQB: SABOF) announced a strategic content partnership between its Creator Television network and MADCOOL Media to produce scripted and unscripted series across genres with a focus on diverse creators.Original series will be distributed on Creator Television via Xumo Play, Amazon Fire TV Channels, Sling Freestream, Plex, and LiveTVx, with combined reach of over 65 million viewers globally. The collaboration aims to expand creator-led programming and advertiser-facing inventory while advancing representation in television.

3 months ago

#HURA TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering

www.stocktitan.net/news/HURA/tu-hura-biosci...

0 0 0 0

3 months ago

#HURA: Third Quarter Results buff.ly/cyZK53w

0 0 0 0

Stribog

@stribog666.bsky.social

4 months ago

Práve sme vyriešili problém bezdomovcov v štáte #Slovensko

#hura #radost #fico #kkt #smer #agent #hanba

14 1 0 0

Jakub

@manijakcz.bsky.social

6 months ago

Cherry rajčátka

Úplně poprvý jsem v obchodě viděl volně vysypaný cherry rajčátka, že si jich můžeš nabrat kolik chceš a nemusíš si kupovat celou tu vaničku, kterou víš, že nesníš (a pak se o ní dělíš s kolegyní). V Lidlu někdo konečně přemýšlel. #hura

22 0 2 0

@nasdaq.activitypub.awakari.com.ap.brid.gy

6 months ago

#HURA: IFx-2.0 Phase III Begins buff.ly/aZ8R2Mu

0 0 0 0

Nasdaq

7 months ago

TuHURA R&D Jumps 75% in Q2 | The Motley Fool

#HURA #189566ab-7229-49df-ac1f-9d4e40298ce4 #data-news

Origin | Interest | Match

0 0 0 0

TuHURA's Cancer Drug Enters FDA Fast Track Trial as Company Expands Immunotherapy Pipeline Immuno-oncology firm advances MCC cancer treatment under FDA accelerated approval pathway, acquires novel VISTA platform, and secures $15.5M in fresh capital. See pipeline details.

7 months ago

#HURA TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

www.stocktitan.net/news/HURA/tu-hura-biosci...

0 0 0 0

Rising Biotech TuHURA Joins Russell 3000, Accelerates Phase 3 Cancer Immunotherapy Trial New Russell 3000 member TuHURA advances Phase 3 trial for Merkel cell carcinoma while integrating novel VISTA antibody acquisition. See growth catalysts.

8 months ago

#HURA TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

www.stocktitan.net/news/HURA/tu-hura-biosci...

0 0 0 0

TuHURA Biosciences Completes Acquisition of Kineta TuHURA Biosciences (NASDAQ:HURA) has successfully completed the acquisition of Kineta, Inc. (OTCPK:KANT), adding a Phase 2 ready VISTA inhibiting monoclonal antibody to its immuno-oncology pipeline. The acquired drug candidate, formerly known as KVA1213, has been renamed to TBS-2025.The acquisition unlocks the fourth tranche of funds from a previously announced $12.5 million PIPE financing. TuHURA plans to initiate a Phase 2 randomized trial in the second half of 2025, investigating TBS-2025 in combination with a menin inhibitor for NPM1 mutated AML treatment.The strategic acquisition provides synergies with TuHURA's antibody drug conjugate (ADC) technology. The company is exploring the possibility of conjugating TBS-2025 with Delta Opioid Receptor inhibitors to create a bi-functional, bi-specific ADC targeting myeloid derived suppressor cells in the tumor microenvironment.

8 months ago

#HURA #KANT TuHURA Biosciences Completes Acquisition of Kineta

www.stocktitan.net/news/HURA/tu-hura-biosci...

0 0 0 0

TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals TuHURA Biosciences (NASDAQ:HURA), a Phase 3 immune-oncology company, and Kineta (OTC Pink:KANT), a clinical-stage biotechnology company, announced that stockholders of both companies have approved their proposed merger. At TuHURA's Special Meeting, stockholders approved increasing authorized shares to 200 million and reincorporating in Delaware. The merger is expected to close upon satisfaction of remaining closing conditions.Both companies specialize in developing novel immunotherapies in oncology, focusing on addressing cancer immune resistance. The final voting results will be reported in Current Reports on Form 8-K with the SEC.

8 months ago

#HURA #KANT TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals

www.stocktitan.net/news/HURA/tu-hura-biosci...

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

9 months ago

Investigation by Halper Sadeh LLC Targets HURA and VIGL Shareholder Rights Halper Sadeh LLC is investigating TuHURA and Vigil Neuroscience for potential shareholder rights violations. This inquiry seeks to protect investor interests and ensure compliance with securities laws.

Investigation by Halper Sadeh LLC Targets HURA and VIGL Shareholder Rights #USA #New_York #Halper_Sadeh #HURA #VIGL

0 0 0 0

FDA Green Light: Revolutionary Cancer Immunotherapy Combo Trial to Begin for Rare Skin Cancer FDA removes hold on breakthrough cancer treatment combining IFx-2.0 with Keytruda. Phase 3 trial for advanced Merkel cell carcinoma starts June 2025. See trial design.

9 months ago

#HURA FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma

www.stocktitan.net/news/HURA/fda-removes-pa...

0 0 0 0

TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting TuHURA Biosciences (NASDAQ:HURA) presented a Phase 3 trial-in-progress poster at ASCO 2025 for IFx-Hu2.0, a novel innate immune agonist being developed as adjunctive therapy with Keytruda in checkpoint inhibitor-naïve patients with advanced Merkel cell carcinoma (MCC). The Phase 3 trial, operating under FDA's Accelerated Approval Pathway and Special Protocol Assessment agreement, will enroll 118 patients across 22-25 U.S. sites. Previous Phase 1b results showed promising efficacy with a 63% overall response rate in MCC patients who progressed on prior therapy. The randomized, double-blinded trial will evaluate IFx-Hu2.0 (0.1mg) administered weekly for three weeks with pembrolizumab versus pembrolizumab plus placebo, with overall response rate as the primary endpoint.

9 months ago

#HURA TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting

www.stocktitan.net/news/HURA/tu-hura-biosci...

0 0 0 0

9 months ago

#HURA: First Quarter 2025 Results buff.ly/saz68nB

0 0 0 0

TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update TuHURA Biosciences (NASDAQ:HURA) reported Q1 2025 financial results and corporate updates. The company plans to initiate a Phase 3 accelerated approval trial of IFx-Hu2.0 with Keytruda for Merkel cell carcinoma (MCC) in Q2 2025. TuHURA has already initiated a Phase 1b/2a trial for MCC of unknown primary origin (MCCUP). The company aims to acquire Kineta Inc. in Q2 2025 and launch a Phase 2 trial of Kineta's VISTA inhibitor antibody for NPM1-mutated AML in Q3 2025. Financial results show R&D expenses of $4.6M and G&A expenses of $2.4M for Q1 2025. The company has approximately 43.7M total shares outstanding and expects four major clinical data readouts over the next 24 months.

9 months ago

#HURA #KANT TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update

www.stocktitan.net/news/HURA/tu-hura-biosci...

0 0 0 0

BílýŠťastnýDrak

@furchur.bsky.social

10 months ago

Poslední ambulanti odbaveni. Začíná 2 tydenní dovolená 😎🏝
#hura #radost #relax

40 0 1 0

Small Cap Strategist

@smcapstrategist.bsky.social

10 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks in new uptrend according to average directional index, Mon Apr 21st - #GROY #HURA #UPXI #SIEB #PAMT #OESX #NDRA #AVTE #APM #NMG #KUKE #FRGE - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

11 months ago

#HURA: 2024 Financial Results buff.ly/YNW87Ua

0 0 0 0

TuHURA Advances Two Cancer Immunotherapy Programs: Key Clinical Data Coming at AACR 2025 New Phase 1 results for anti-VISTA antibody KVA12123 and melanoma therapy IFx-Hu2.0 showcase TuHURA's expanding cancer immunotherapy pipeline. Full analysis inside.

11 months ago

#HURA #KANT TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting

www.stocktitan.net/news/HURA/tu-hura-biosci...

1 0 0 0